<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004899</url>
  </required_header>
  <id_info>
    <org_study_id>NU 91H1T</org_study_id>
    <secondary_id>NU-91H1T</secondary_id>
    <secondary_id>NCI-G00-1688</secondary_id>
    <nct_id>NCT00004899</nct_id>
  </id_info>
  <brief_title>Chemotherapy Plus Bone Marrow Transplantation and Filgrastim in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome</brief_title>
  <official_title>Autologous Bone Marrow Transplantation for Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome - A Phase II Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing and die. Bone marrow transplantation may be able to replace cells that&#xD;
      were destroyed by chemotherapy. Colony-stimulating factors such as filgrastim may increase&#xD;
      the number of immune cells found in bone marrow or peripheral blood and may help a person's&#xD;
      immune system recover from the side effects of chemotherapy.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of chemotherapy plus bone marrow&#xD;
      transplantation and filgrastim in treating patients who have acute myelogenous leukemia or&#xD;
      myelodysplastic syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the overall survival and disease free survival of patients with acute&#xD;
           myelogenous leukemia or myelodysplastic syndrome treated with busulfan and etoposide&#xD;
           followed by autologous bone marrow transplantation and filgrastim (G-CSF).&#xD;
&#xD;
        -  Assess the toxicities of this regimen in this patient population.&#xD;
&#xD;
        -  Assess the hematologic effects and toxicities of G-CSF given in this setting to these&#xD;
           patients.&#xD;
&#xD;
        -  Determine whether G-CSF stimulates leukemic relapse in these patients.&#xD;
&#xD;
        -  Determine whether G-CSF has an affect on platelet recovery in this setting in these&#xD;
           patients.&#xD;
&#xD;
      OUTLINE: Patients are stratified according to first, second, or third remission. Patients&#xD;
      undergo bone marrow collection.&#xD;
&#xD;
      Patients receive oral busulfan every 6 hours for 16 doses on days -5, -4, -3, and -2.&#xD;
      Patients receive etoposide IV over 4 hours on days -4, -3, and -2. Bone marrow is reinfused&#xD;
      36-48 hours after the last dose of etoposide. Patients receive filgrastim (G-CSF) IV daily&#xD;
      beginning 2-4 hours after bone marrow reinfusion until hematopoietic recovery.&#xD;
&#xD;
      Patients are followed monthly for 1 year, every 3 months for 1 year, and then every 6 months&#xD;
      thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 20-30 patients will be accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1999</start_date>
  <completion_date type="Actual">August 2004</completion_date>
  <primary_completion_date type="Actual">August 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic/Myeloproliferative Diseases</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous bone marrow transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Morphologically proven (from bone marrow aspirate smears or touch preps of marrow&#xD;
             biopsy) of myelodysplastic syndrome or acute myelogenous leukemia (AML) of 1 of the&#xD;
             following subtypes:&#xD;
&#xD;
               -  Acute myeloblastic leukemia (FAB M1 or M2)&#xD;
&#xD;
               -  Acute promyelocytic leukemia (FAB M3)&#xD;
&#xD;
               -  Acute myelomonocytic leukemia (FAB M4)&#xD;
&#xD;
               -  Acute monocytic leukemia (FAB M5)&#xD;
&#xD;
               -  Acute erythroleukemia (FAB M6)&#xD;
&#xD;
          -  In complete remission at time of marrow or stem cell harvesting&#xD;
&#xD;
          -  No relapsed AML unless bone marrow or peripheral blood stem cells previously harvested&#xD;
             in remission are available for transplantation&#xD;
&#xD;
          -  May have had secondary AML that is either therapy related or that has evolved from an&#xD;
             antecedent myelodysplastic syndrome&#xD;
&#xD;
          -  History of CNS disease during induction allowed provided inactive and cytologic&#xD;
             examination of spinal fluid from preharvest lumbar puncture shows no evidence of&#xD;
             leukemia&#xD;
&#xD;
          -  No occult or symptomatic leukemic meningitis during induction therapy or prior to bone&#xD;
             marrow harvesting&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Physiologic 65 and under&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
          -  Creatinine clearance at least 50 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  Cardiac ejection fraction normal&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  FEV1 at least 60% predicted&#xD;
&#xD;
          -  DLCO at least 60% predicted&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No evidence of persistent infections&#xD;
&#xD;
          -  No concurrent organ damage or medical problems that would preclude study therapy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No concurrent antibiotics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin S. Tallman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Robert H. Lurie Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center at Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>March 7, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <disposition_first_submitted>February 16, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>February 16, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 18, 2011</disposition_first_posted>
  <last_update_submitted>June 8, 2012</last_update_submitted>
  <last_update_submitted_qc>June 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>childhood acute myeloid leukemia in remission</keyword>
  <keyword>adult acute erythroid leukemia (M6)</keyword>
  <keyword>adult acute myeloblastic leukemia without maturation (M1)</keyword>
  <keyword>adult acute myeloblastic leukemia with maturation (M2)</keyword>
  <keyword>adult acute promyelocytic leukemia (M3)</keyword>
  <keyword>adult acute myelomonocytic leukemia (M4)</keyword>
  <keyword>adult acute monoblastic leukemia (M5a)</keyword>
  <keyword>childhood acute myeloblastic leukemia without maturation (M1)</keyword>
  <keyword>childhood acute myeloblastic leukemia with maturation (M2)</keyword>
  <keyword>childhood acute promyelocytic leukemia (M3)</keyword>
  <keyword>childhood acute myelomonocytic leukemia (M4)</keyword>
  <keyword>childhood acute monoblastic leukemia (M5a)</keyword>
  <keyword>childhood acute monocytic leukemia (M5b)</keyword>
  <keyword>childhood acute erythroleukemia (M6)</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>adult acute monocytic leukemia (M5b)</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>myelodysplastic/myeloproliferative disease, unclassifiable</keyword>
  <keyword>atypical chronic myeloid leukemia</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>childhood myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

